{
    "id": "MISSION-500-152-1771351338439",
    "type": "priorityAction",
    "difficulty": "4-5",
    "topic": "Neuroleptic Malignant Syndrome",
    "text": "The nurse is caring for a 38-year-old male client with a history of schizophrenia and type 2 diabetes mellitus who was admitted from a supported housing facility due to acute confusion and stiffness. The nurse has just reviewed the client's new laboratory results and electrocardiogram (ECG) report.",
    "prompt": "Which action is the priority for the nurse to take?",
    "tabs": [
        {
            "id": "ehr",
            "name": "EHR",
            "content": [
                {
                    "type": "nursesNote",
                    "time": "14:00",
                    "header": "Emergency Department Nurse's Note",
                    "body": "Client brought in by staff from supported housing facility for 'not acting right' over the past 24 hours. Client is diaphoretic, minimally responsive to verbal stimuli, and demonstrates significant generalized 'lead-pipe' muscle rigidity. Staff reports client has had difficulty swallowing and has refused fluids today. Lungs clear to auscultation. Skin is hot and moist to the touch."
                },
                {
                    "type": "mar",
                    "header": "Medication Administration Record",
                    "records": [
                        {
                            "name": "Olanzapine",
                            "dose": "15 mg",
                            "route": "PO",
                            "frequency": "Daily",
                            "timeDue": "16:00",
                            "notes": "Administer for schizophrenia"
                        },
                        {
                            "name": "Metformin",
                            "dose": "1000 mg",
                            "route": "PO",
                            "frequency": "BID",
                            "timeDue": "20:00",
                            "notes": "Administer for type 2 diabetes"
                        },
                        {
                            "name": "Acetaminophen",
                            "dose": "650 mg",
                            "route": "PO/PR",
                            "frequency": "q4h PRN",
                            "timeDue": "PRN",
                            "notes": "For fever > 38.0 C"
                        }
                    ]
                }
            ]
        },
        {
            "id": "vitals",
            "name": "Vital Signs",
            "content": [
                {
                    "type": "trendTable",
                    "header": "Vital Signs Trend",
                    "rows": [
                        {
                            "label": "Time",
                            "values": [
                                "14:05",
                                "15:00",
                                "15:45"
                            ]
                        },
                        {
                            "label": "Temperature (°C)",
                            "values": [
                                "38.8",
                                "39.4",
                                "40.1"
                            ]
                        },
                        {
                            "label": "Heart Rate (/min)",
                            "values": [
                                "118",
                                "126",
                                "132"
                            ]
                        },
                        {
                            "label": "Blood Pressure (mmHg)",
                            "values": [
                                "155/90",
                                "168/98",
                                "140/85"
                            ]
                        },
                        {
                            "label": "Respiratory Rate (/min)",
                            "values": [
                                "24",
                                "28",
                                "30"
                            ]
                        },
                        {
                            "label": "SpO2 (%)",
                            "values": [
                                "95%",
                                "94%",
                                "94%"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "id": "labs",
            "name": "Labs",
            "content": [
                {
                    "type": "table",
                    "header": "Laboratory Results (STAT)",
                    "rows": [
                        {
                            "label": "Potassium",
                            "value": "7.1 mEq/L",
                            "range": "3.5-5.0 mEq/L"
                        },
                        {
                            "label": "Creatine Kinase (CK)",
                            "value": "28,500 U/L",
                            "range": "30-200 U/L"
                        },
                        {
                            "label": "BUN",
                            "value": "38 mg/dL",
                            "range": "10-20 mg/dL"
                        },
                        {
                            "label": "Creatinine",
                            "value": "2.9 mg/dL",
                            "range": "0.6-1.2 mg/dL"
                        },
                        {
                            "label": "WBC Count",
                            "value": "16.8 x 10³/μL",
                            "range": "4.5-11.0 x 10³/μL"
                        },
                        {
                            "label": "Troponin I",
                            "value": "<0.04 ng/mL",
                            "range": "<0.04 ng/mL"
                        }
                    ]
                }
            ]
        },
        {
            "id": "diagnostics",
            "name": "Diagnostics",
            "content": [
                {
                    "type": "text",
                    "header": "12-Lead ECG Interpretation",
                    "body": "Sinus tachycardia at 130 bpm. PR and QRS intervals are within normal limits. Prominent, narrow, peaked T waves are noted across precordial leads. No ST segment elevation or depression."
                }
            ]
        }
    ],
    "options": [
        {
            "id": "opt_05",
            "text": "Increase the rate of the maintenance IV fluids."
        },
        {
            "id": "opt_06",
            "text": "Place the client on a cardiac monitor."
        },
        {
            "id": "opt_01",
            "text": "Administer the scheduled 16:00 dose of olanzapine."
        },
        {
            "id": "opt_03",
            "text": "Apply a hypothermia blanket and administer PR acetaminophen."
        },
        {
            "id": "opt_04",
            "text": "Request a prescription for IV dantrolene."
        },
        {
            "id": "opt_02",
            "text": "Prepare to administer IV calcium gluconate."
        }
    ],
    "correct": [
        "opt_02"
    ],
    "answerBreakdown": {
        "analyzeCues": "The nurse must synthesize data from all tabs. The client's history (schizophrenia, on olanzapine) combined with the clinical presentation (hyperthermia >40°C, extreme muscle rigidity, altered mental status, autonomic instability with tachycardia and labile BP) strongly indicates Neuroleptic Malignant Syndrome (NMS). The laboratory results confirm this and reveal life-threatening complications: extremely high CK (28,500 U/L) indicates severe rhabdomyolysis, and elevated BUN/Creatinine (38/2.9 mg/dL) shows acute kidney injury (AKI). The most immediate life-threatening finding ('The Killer') is the critical hyperkalemia (7.1 mEq/L) resulting from rhabdomyolysis and AKI. This is corroborated by the ECG finding of peaked T waves, a classic sign of hyperkalemic cardiotoxicity, which can rapidly progress to ventricular fibrillation and asystole.",
        "takeAction": "The priority action must address the most immediate threat to life. While NMS requires a multi-faceted approach, the severe hyperkalemia and its cardiac effects are the most urgent problem. Administering IV calcium gluconate is the priority because it directly stabilizes the cardiac membrane, reducing the risk of fatal dysrhythmias. This is a temporizing measure that 'buys time' for other treatments (like insulin/dextrose) to lower the serum potassium level. All other actions are either contraindicated, less urgent, or do not address the immediate threat of cardiac arrest.",
        "optionsRationale": [
            {
                "id": "opt_01",
                "rationale": "Incorrect. This is a critical 'DON'T PROCEED' / 'SAFETY STOP' error. Olanzapine, an antipsychotic, is the presumed causative agent of the NMS. Administering another dose would worsen the syndrome and is absolutely contraindicated."
            },
            {
                "id": "opt_02",
                "rationale": "Correct. This is the priority nursing action. With a potassium level of 7.1 mEq/L and ECG changes (peaked T waves), the client is at immediate risk of cardiac arrest. IV calcium gluconate is the first-line emergency treatment to stabilize the myocardium and prevent lethal arrhythmias. The nurse should anticipate this order and prepare for administration."
            },
            {
                "id": "opt_03",
                "rationale": "Incorrect. While treating hyperthermia is a key component of NMS management, it is not the immediate priority over preventing cardiac arrest from hyperkalemia. Cooling measures should be initiated, but only after addressing the cardiotoxic emergency."
            },
            {
                "id": "opt_04",
                "rationale": "Incorrect. Dantrolene is a muscle relaxant used to treat the rigidity and hypermetabolism of NMS. While it is an indicated treatment for the underlying syndrome, its onset is not as rapid as calcium gluconate, and it does not directly correct the life-threatening hyperkalemia. Stabilizing the heart is the immediate priority."
            },
            {
                "id": "opt_05",
                "rationale": "Incorrect. Aggressive IV hydration is essential for managing rhabdomyolysis and AKI by flushing myoglobin through the kidneys. However, this action will not correct the critically high potassium level quickly enough to prevent a cardiac event. It is a necessary intervention, but secondary to cardiac stabilization."
            },
            {
                "id": "opt_06",
                "rationale": "Incorrect. While the client absolutely must be on a continuous cardiac monitor, this is an assessment and monitoring action, not a therapeutic intervention. Given the critical lab and ECG data, a direct action to prevent clinical deterioration is required. The question asks what the nurse should do, implying an intervention. Preparing a life-saving medication is a higher priority than the act of placing monitor leads, which should have already been done or is done concurrently."
            }
        ]
    }
}